Trial population
SARS-COV-2 INFECTION
The study was conducted in Melbourne, recruiting from April to November 2022. 103 adults aged 18–64 years previously vaccinated with 3 doses of licensed SARS-CoV-2 ancestral strain vaccines were screened, resulting in 76 eligible participants, (participant demographics shown in Baseline demographics, prior COVID and vaccination.Note: Other race includes White-caucasian/European Heritage, African/White and White/Asian.Prior SARS-CoV-2 infection was reported in 28 participants (37%, 